<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110590</url>
  </required_header>
  <id_info>
    <org_study_id>14612</org_study_id>
    <secondary_id>2009-015894-11</secondary_id>
    <nct_id>NCT01110590</nct_id>
  </id_info>
  <brief_title>Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Group-comparison, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administration of Different Doses of Vardenafil (2 Dose Strengths) and BAY60-4552 (4 Dose Strengths) Given Once-daily (od) Over 14 Days in Patients With Erectile Dysfunction (ED).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in this
      multiple dose escalation study. In three treatments groups different dosages of BAY 60-4552
      and vardenafil will be given with patients with erectile dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event reporting</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of study drugs; Pharmacokinetic parameters: AUC, Cmax, AUC/D, Cmax;norm, Cmax/D, t1/2, tmax</measure>
    <time_frame>Day 0, 6, 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>Day 0, 6, 13</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY60-4552 + Vardenafil</intervention_name>
    <description>Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY60-4552 + Vardenafil</intervention_name>
    <description>Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY60-4552 + Vardenafil</intervention_name>
    <description>Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The informed consent must be signed before any study specific tests or procedures are
             done

          -  Male patients with a history of erectile dysfunction (ED) for at least 6 months,
             defined as &quot;the inability to achieve and maintain an erection of the penis sufficient
             to complete satisfactory sexual intercourse&quot; by the NIH consensus report 1993. The
             diagnosis of 'Erectile dysfunction' has to be confirmed by a physician

          -  Age: 18 to 70 years (inclusive) at the first screening examination

          -  Ethnicity: White

          -  Body mass index (BMI): equal to or above 18 and below 32 kg / m²

          -  Confirmation of the patient's health insurance coverage prior to the first screening
             examination / visit

          -  Ability to understand and follow study-related instructions

        Exclusion Criteria:

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination and effects of the study drugs will
             not be normal

          -  Known hypersensitivity to the study drugs (active substances or excipients of the
             preparations)

          -  Known severe allergies, non-allergic drug reactions, or multiple drug allergies

          -  Any underlying cardiovascular condition, including unstable angina pectoris that would
             preclude sexual activity according to the NIH consensus report 1993

          -  History of myocardial infarction, stroke or life-threatening arrhythmia within 6
             months prior to screening

          -  Bleeding disorder

          -  History of prostatectomy because of prostate cancer, including nerve-sparing
             techniques. Clarification: Any surgical procedures for the treatment of Benign
             Prostate Hypertrophy (BPH) are permitted, with the exception of cryosurgery,
             cryotherapy or cryoablation

          -  Hereditary degenerative retinal disorders such as retinitis pigmentosa

          -  History of loss of vision because of NAION (Bayer Study 12912), temporary or permanent
             loss of vision, including unilateral loss of vision

          -  History of uni- or bilateral hearing loss
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mönchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Pharmacology</name_title>
    <organization>Bayer HealthCare AG</organization>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

